ringer lactate - roztwór do infuzji
baxter polska sp. z o.o. - natrii chloridum + kalii chloridum + calcii chloridum dihydricum + sodu mleczan - roztwór do infuzji - -
solutio ringeri lactate fresenius - roztwór do infuzji
fresenius kabi polska sp. z o.o. - calcii chloridum,kalii chloridum,natrii chloridum,natrii lactas - roztwór do infuzji - -
płyn ringera z mleczanami fresenius - roztwór do infuzji
fresenius kabi polska sp. z o.o. - natrii chloridum + kalii chloridum + calcii chloridum dihydricum + natrii lactas - roztwór do infuzji - -
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroksysmal - selektywne leki immunosupresyjne - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
aspaveli
swedish orphan biovitrum ab (publ) - pegcetacoplan - hemoglobinuria, paroksysmal - leki immunosupresyjne - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.
entemulin 450 mg/g granulat do podania w wodzie do picia 450 mg/g granulat do podania w wodzie do picia
krka, d.d., novo mesto d.o.o. - tiamulini hydrogenofumaras - granulat do podania w wodzie do picia - 450 mg/g - indyk; kura; świnia
solderol 800 j.m. tabletki powlekane
przedsiębiorstwo farmaceutyczne lek-am sp. z o.o. - cholecalciferolum - tabletki powlekane - 800 j.m.
solderol 1000 j.m. tabletki powlekane
przedsiębiorstwo farmaceutyczne lek-am sp. z o.o. - cholecalciferolum - tabletki powlekane - 1000 j.m.
solderol 30000 j.m. tabletki powlekane
przedsiębiorstwo farmaceutyczne lek-am sp. z o.o. - cholecalciferolum - tabletki powlekane - 30000 j.m.
solderol 7000 j.m. tabletki powlekane
przedsiębiorstwo farmaceutyczne lek-am sp. z o.o. - cholecalciferolum - tabletki powlekane - 7000 j.m.